A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

Current Medical Research and Opinion

Volumn 18, Issue 2, 2002, Pages 82-91

  Gertz, Barry J ^a   Krupa, David ^a   Bolognese, James A ^a   Sperling, Rhoda S ^a   Reicin, Alise ^a  

^a NONE   (United States)

Author keywords

COX 2 inhibitors; Edema; Hypertension; NSAIDs; Renovascular safety

Indexed keywords

DICLOFENAC; IBUPROFEN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA BASE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LEG EDEMA; MALE; OSTEOARTHRITIS; RENOVASCULAR DISEASE; WEIGHT GAIN;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; EDEMA; FEMALE; HUMANS; HYPERTENSION; IBUPROFEN; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RENAL CIRCULATION; SAFETY; SULFONES;

EID: 0036244685     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000354     Document Type: Article

References (45)

1. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclo-oxygenase-2
2. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
3. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
4. Analgesic efficacy of the cyclooxygenase-2 specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
5. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial
6. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
7. Efficacy of single dose and multiple dose rofecoxib in the treatment of post-orthopedic surgery pain
8. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
9. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with ostearthritis of the knee and hip
10. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
11. Rofecoxib, a new cycloox-genase-2 inhibitor shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis
12. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis
13. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
14. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
15. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
16. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial
17. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double-blind crossover study comparing rofecoxib with placebo and indomethacin
18. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
19. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
20. Effects of nons-teroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
21. The renal effects of nonsteroidal anti-inflammatory drugs: Summary and recommendations
22. Nonsteroidal anti-inflammatory drugs: Effects on kidney function
23. NSAIDs associated with increases risk of congestive heart failure in elderly patients taking diuretics
24. Nonsteroidal anti-inflammatory drugs and hypertension - The risks in perspective
25. Renal effects of COX-2 selective inhibitors
26. Effect of age on renal responses to COX-2 inhibitors, rofecoxib (VIOXX, MK-0966), celecoxib and meloxicam, in conscious dogs
27. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
28. Effects of celecoxib and naproxen on renal function in the elderly
29. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics
30. Effect of cyclooxygenase inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
31. Acute renal failure related to high-dose celecoxib. Letter to the Editor
32. COX-2 inhibitors and renal failure: The triple whammy revisited
33. Selective COX-2 inhibitors and nephrotoxicity
34. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib
35. Do nonsteroidal and inflammatory drugs affect blood pressure?
36. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure
37. Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned?
38. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy
39. Effects of the COX-2 specific inhibitor celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibition
40. NSAIDs and nephrotoxicity in the elderly
41. NSAIDs and the elderly: Toxicity and economic implications
42. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs